Shots:
- Viatris has entered into a definitive agreement to acquire Pacira BioSciences, advancing its innovative medicines strategy and becoming a leader in non-opioid pain therapies
- As per the deal, Viatris will acquire Pacira for $36.5/share in cash, representing an aggregate equity value of $1.65B, with remaining shares acquired later via a second-step merger; closing is expected by the end of 2026
- Viatris plans to leverage its IP expertise & lifecycle-management capabilities to maximize the long-term value of Pacira’s two established, high-margin, patent-protected US products, Exparel & Zilretta, while expanding their reach into select international markets
Ref: PRnewswire | Image: Pacira Biosciences | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
